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Abstract
Background: Progressive remodeling after myocardial infarction (MI) is a leading cause of morbidity and mortality.
Recently, glucagon-like peptide (GLP)-1 was shown to have cardioprotective effects, but treatment with GLP-1 is
limited by its short half-life. It is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4), an enzyme which
inhibits GLP-1 activity. We hypothesized that the DPP-4 inhibitor vildagliptin will increase levels of GLP-1 and may
exert protective effects on cardiac function after MI.
Methods: Sprague-Dawley rats were either subjected to coronary ligation to induce MI and left ventricular (LV)
remodeling, or sham operation. Parts of the rats with an MI were pre-treated for 2 days with the DPP-4 inhibitor
vildagliptin (MI-Vildagliptin immediate, MI-VI, 15 mg/kg/day). The remainder of the rats was, three weeks after
coronary artery ligation, subjected to treatment with DPP-4 inhibitor vildagliptin (MI-Vildagliptin Late, MI-VL) or
control (MI). At 12 weeks, echocardiography and invasive hemodynamics were measured and molecular analysis
and immunohistochemistry were performed.
Results: Vildagliptin inhibited the DPP-4 enzymatic activity by almost 70% and increased active GLP-1 levels by
about 3-fold in plasma in both treated groups (p < 0.05 vs. non-treated groups). Cardiac function (ejection fraction)
was decreased in all 3 MI groups compared with Sham group (p < 0.05); treatment with vildagliptin, either early or
late, did not reverse cardiac remodeling. ANP (atrial natriuretic peptide) and BNP (brain natriuretic peptide) mRNA
levels were significantly increased in all 3 MI groups, but no significant reductions were observed in both
vildagliptin groups. Vildagliptin also did not change cardiomyocyte size or capillary density after MI. No effects
were detected on glucose level and body weight in the post-MI remodeling model.
Conclusion: Vildagliptin increases the active GLP-1 level via inhibition of DPP-4, but it has no substantial protective
effects on cardiac function in this well established long-term post-MI cardiac remodeling model.
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Introduction
Glucagon-like peptide-1(GLP-1; 7-36 amide), which
belongs to the proglucagon family of incretin peptides,
is secreted by enteroendocrine L cells of the intestinal
mucosa and released in response to food intake [1].
GLP-1 analogues have been used for the clinical treat-
ment of type 2 diabetes because of its multiple actions
on pancreatic function [2-4]. Besides its effects on glu-
cose metabolism, GLP-1 has been proven to exert
cardiovascular effects in clinical and experimental stu-
dies, in the presence or absence of diabetes [5].
GLP-1 receptors (GLP-1R) are expressed in rodent
and human heart and vasculature [6-8]. GLP-1R defi-
cient mice exhibit increased left ventricular (LV) thick-
ness, impaired LV contractility and LV diastolic
function compared with control mice [9]. However,
whether the beneficial effects of GLP-1 on the heart
are conferred through direct GLP-1R signaling or
indirect, through the GLP-1R-dependent improvement
in glucose metabolism is not well established. Admin-
istration of GLP-1 improves myocardial function and
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injury or heart failure. GLP-1 increased cardiac output,
and reduced LV end diastolic pressure, in association
with improved myocardial insulin sensitivity and myo-
cardial glucose uptake in dogs with rapid pacing-
induced congestive heart failure [10]. Consistent with
the cytoprotective action of GLP-1 in the endocrine
pancreas, GLP-1 reduced infarct size in the isolated
perfused rat heart and in animal models of myocardial
ischemia [11-13]. A 72 hours infusion of GLP-1 in
patients with acute myocardial infarction (MI) and an
LV ejection fraction (LVEF) less than 40% resulted in
significantly improved LVEF and improved regional
and global wall motion scores, in association with a
trend towards earlier hospital discharge [14]. In a pilot
study of both diabetic and non-diabetic subjects with
heart failure, an improved LV function was observed
following a 5 week continuous infusion of GLP-1(7-36)
[5].
However, active GLP-1 in the circulation is rapidly
(within two minutes) degraded by dipeptidyl peptidase-4
(DPP-4) [15]. An alternative approach for enhancing
GLP-1 action involves the use of DPP-4 inhibitors. The
DPP-4 inhibitor sitagliptin [16] and saxagliptin [17] have
been approved for type 2 diabetic patients. Vildagliptin
is only approved and used in Europe [18].
The studies on cardiovascular effects of GLP-1, dis-
cussed above, have consequently assessed only short-
term improvements in cardiac performance, like in post-
ischemic or cardiomyopathy states. There are no reports
on long-term effects of DPP-4 inhibition in a post-MI
cardiac remodeling model. Furthermore, the actions of
DPP-4 inhibitors on cardiac remodeling after MI are
incompletely understood. We hypothesized that the
DPP-4 inhibitor vildagliptin may exert beneficial effects
on infarcted hearts by inhibiting the degradation of
active GLP-1 and other cardiovascular peptides. The
purpose of our study was therefore to determine
whether vildagliptin has beneficial effects on long-term
post-MI remodeling in rats and to explore the mechan-
isms underpinning these effects.
Methods and materials
Animals
Male Sprague-Dawley rats (Harlan, Zeist, The Nether-
lands) weighing 250-260 g were housed in groups of
4-5 on a 12-hour light-dark cycle with standard rat
chow and water available ad libitum. The animals
were subjected to sham-surgery or left coronary artery
ligation. All experiments were carried out after
approval of the Animal Ethical Committee of the Uni-
versity of Groningen for the use of experimental ani-
mals and conform to the Guide for Care and Use of
Laboratory Animals.
Drugs
The DPP-4 inhibitor vildagliptin was kindly supplied by
Novartis, The Netherlands. Vildagliptin was dissolved in
the drinking water and administered in a final concen-
tration of 15 mg/kg/day, which is chosen according to
the previous studies [19,20].
Experimental protocol
Rats were randomly subjected to induction of MI or
sham surgery. Briefly, animals were intubated and
mechanically ventilated with 2.5% isoflurane in room air
enriched with 1.0 L/min oxygen. After left-sided thora-
cotomy, MI was induced by ligating the proximal por-
tion of the left coronary artery. In sham-operated rats,
the same surgery was performed without ligating the
suture. Parts of the rats with MI were pre-treated for 2
days with vildagliptin (MI-Vildagliptin immediate, MI-
VI). The remainder of the rats was, three weeks after
coronary artery ligation, subjected to treatment with
DPP-4 inhibitor vildagliptin (MI-Vildagliptin Late, MI-
VL) or control (MI). At week 12, cardiac function was
determined by echocardiography. After 12 weeks, rats
were anaesthetized and hemodynamic function was
measured invasively; thereafter blood was drawn (either
anticoagulated with EDTA, or left to clot for serum)
and the hearts were rapidly excised. Myocardial tissue
was sectioned transversally and processed for immuno-
histochemistry or snap-frozen for molecular analysis.
Echocardiographic measurements
Cardiac function was assessed by echocardiography by a
Vivid 7 (GE Healthcare) equipped with a 10-MHz phase
array linear transducer. The echocardiographic measure-
ments were performed under general anaesthesia with
2.5% isoflurane, by a researcher blinded for the treat-
ment allocation. Both 2-dimensional (2D) images in
parasternal long-axis and short-axis view and 2-D
guided M-mode tracings were obtained. Short-axis views
were recorded at the level of mid-papillary muscles. LV
internal dimensions in diastole and systole (LVIDd and
LVIDs) were measured using M-mode and calculated
from three cardiac cycles. LV fractional shortening (FS
%) was calculated as follows: FS = (LVIDd-LVIDs)/
LVIDd×100%. LV ejection fraction (EF %) was calculated
using the Teichholz method.
Hemodynamic measurements
At sacrifice, rats were anesthetized and a micro-tip pres-
sure transducer (Millar Instr. Inc., Houston, TX, USA)
was inserted into the right carotid artery. Arterial systo-
lic and diastolic blood pressures (SBP, DBP) were
recorded in the aortic arch. The catheter was advanced
into the LV cavity. After a 5-min period of stabilization,
heart rate (HR), LV systolic pressure (LVSP), LV end-
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(dLVP = LVSP-LVEDP) were measured. For indices of
contractility and relaxation, the maximal rates of
increase and decrease in LVP dp/dtmax and dp/dtmin
were determined.
Procurement of heart tissue and infarct size measurement
After the rats were euthanized, hearts were rapidly
excised and arrested in diastole in 2 M ice-cold KCl.
The total heart was weighed (heart weight, HW). The
right ventricle and atria were removed, and the left ven-
tricle was weighed (left ventricular weight, LVW). The
basal and apical parts of the LV were snap-frozen in
liquid nitrogen. A mid-papillary slice of the LV was
fixed in 4% paraformaldehyde overnight and paraffin-
embedded. Paraffin blocks were sectioned, and slides
were dehydrated. The 5 μm sections were stained with
picrosirius red/fast green [21]. The infarct size was cal-
culated as percentage of the scar length to the total LV
circumference. The images were obtained with a Leica
microscope and analyzed using appropriate software
(Image-pro plus, version 4.5.0.29).
Biomolecular assays
EDTA plasma was used to measure active GLP-1 and
DPP-4 activity, using a commercial Enzyme Linked Immu-
nosorbent Assay, according to the guidelines provided by
the manufacturer (Quantikine, R&D system, London, UK).
Glucose levels were measured with a blood glucose moni-
tor (Accu-Check
®, Roche, Germany). Plasma triglyceride
and cholesterol levels were determined using commercially
available kits (Roche Diagnostics, Mannheim, Germany
and DiaSys Diagnostic Systerms, Holzheim, Germany).
Capillary density
To visualize the capillaries in the myocardium, endothe-
lial cells were stained with Lection GSI (Sigma-Aldrich
Chemie, Zwijndrecht, The Netherlands), as previously
described [22]. Briefly, 5-μm sections were deparaffi-
nised and rehydrated and endogenous peroxidase was
inhibited by methanol/H2O2 (0.3%) for 15 minutes. Sec-
tions were incubated overnight with biotinylated Lectin
GSI (1:100) at room temperature. Then, in a second
step, the signal was intensified with an ABC-complex
containing peroxidase labeled biotins (1:100) (Lab vision,
C A ,U S A ) .F i n a l l y ,t h es e c t ions were incubated with a
Ni-Co amplified DAB solution to which a stable perox-
ide substrate buffer was added (Pierce, CA, USA).
Endothelial cells of capillaries and larger vessels were
visualized in the myocardium as a brown precipitate. A
background staining was not used in order to avoid
interference with the Lectin staining. Capillary density
in the viable LV wall was calculated as the number of
capillaries per tissue area.
Left ventricular hypertrophy
First, left ventricular hypertrophy was expressed as the
ratio of left ventricular weight to body weight. Micro-
scopically, left ventricles were cut into 5 μm transversal
slices from apex to base. Afterwards, sections were
stained with a Gomori’s silver staining in order to visua-
lize the membrane of the cardiomyocytes, as described
previously [21]. Cardiomyocyte size was measured trans-
versally cut in the border zone of the infarcted area
using image analysis (Zeiss KS400, Germany).
Real-time PCR
We used myocardial tissue (of border zone of the infarc-
tion) to extract total RNA with TRIzol reagent (Invitro-
gen Corp., Carlsbad, CA, USA). The nano-drop device
was used to quantify the RNA concentration. First
strand cDNA was synthesized by reverse transcription
reaction by using random primer mix, and used as a
template to amplify genes of interest; for this specific
primers against ANP (atrial natriuretic peptide), BNP
(brain natriuretic peptide), collagen I, MMP-9 (matrix
metalloproteinase-9) were designed. All gene expression
values were normalized to 36B4 mRNA levels.
Data analysis
All data are presented as means ± standard errors of the
mean (sem). Data of infarcted rats were only included if
the infarction comprised the major part of the LV free
wall, since small infarctions (< 20%) are found to be
hemodynamic fully compensated (two animals were
excluded from the MI group, and three animals were
excluded from each vildagliptin-treated groups MI-VI
and MI-VL). Statistical analysis among groups was per-
formed by one-way analysis of variance (ANOVA) fol-
lowed by Tukey post-hoc test. Within-group
comparisons between week 3 and week 12 were ana-
lyzed by Paired-Sample T-Test. Differences were consid-
ered statistically significant if p < 0.05.
Results
Active GLP-1, DPP-4 activity and glucose levels
We measured the DPP-4 activity and active GLP-1
levels in plasma after 12 weeks of vildagliptin treatment
to confirm that continuous administration of vildagliptin
(supplied at 15 mg/kg in the drinking water) was indeed
associated with suppression of plasma DPP-4 activity,
and increase in the active GLP-1 levels. Plasma DPP-4
activity was significantly reduced by almost 70% in both
treatment groups compared to non-treated groups. This
was associated with a significant increase of active GLP-
1 level in both vildagliptin groups (Figure 1).
During the 12 weeks of follow up, we measured glu-
cose levels at baseline, week 6 and week 12. No signifi-
cant changes in glucose levels were observed, suggesting
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The similar findings were observed in plasma choles-
terol and triglycerides that no significant differences
were found among all groups (Table 1B).
Body Weight, LV weight, and infarct Size
Body weight (BW), LV weight (LVW) to body weight
ratios (LVW/BW) and infarct sizes are shown in Table
1A. Ligation of the left coronary artery resulted in an
infarct size of 47 ± 2% in control-treated MI group (Fig-
ure 2B). Although there was no significant reduction in
the infarct size, vildagliptin treatment (both immediate
and late) was associated with a trend towards smaller
infarct size over the 3-month period of treatment com-
pared with the MI control group (Figure 2B). There was
no difference in body weight between groups both at
baseline and at 12 weeks after MI surgery. The LVW/
BW ratios in all MI groups were significantly increased
compared to LVW/BW of the sham-operated group,
however, LV hypertrophy was not significantly reduced
by vildagliptin treatment (both groups) compared to MI
control (Table 1A).
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Figure 1 Effects of Vildagliptin on DPP-4 activity and active GLP-1 levels. A:Vildagliptin increases active plasma GLP-1 levels after 12 weeks
treatment. B: Vildagliptin reduces DPP-4 activity after 12 weeks treatment.Data are presented as means ± SEM. N = 8-10 for all groups. *P < 0.05
vs. sham group; $P < 0.05 vs. MI group.
Table 1 Characteristics of the experimental groups at sacrifice (12 weeks).
Sham
N=8
MI
N=1 0
MI-VI
N=9
MI-VL
N=9
A BW (g)
(baseline)
321 ± 9 313 ± 5 321 ± 2 306 ± 4
BW (g)
(12 week)
446 ± 15 449 ± 11 436 ± 5 450 ± 7
LVW (g)
(12 week)
0.93 ± 0.03 1.05 ± 0.03* 0.97 ± 0.02 1.08 ± 0.03*
LVW/BW 2.00 ± 0.05 2.34 ± 0.09** 2.22 ± 0.05 2.39 ± 0.05**
B Glucose (mmol/L)
(3 week)
9.0 ± 0.6 8.0 ± 0.5 7.8 ± 0.3 9.5 ± 0.4
Glucose (mmol/L)
(6 week)
7.2 ± 0.2 7.3 ± 0.3 7.1 ± 0.1 7.7 ± 0.2
Glucose (mmol/L)
(12 week)
8.0 ± 0.3 7.3 ± 0.2 8.0 ± 0.3 7.6 ± 0.2
Cholesterol (mmol/L) 1.49 ± 0.09 1.48 ± 0.04 1.45 ± 0.08 1.39 ± 0.07
Triglycerides (mmol/L) 0.95 ± 0.19 1.12 ± 0.13 0.84 ± 0.11 0.86 ± 0.12
Data are presented as means ± SEM; N indicates number of animals; BW, body weight; LVW, left ventricle weight; LVW/BW, left ventricle weight/body weight
ratio.**P < 0.01 vs. Sham.*P < 0.05 vs. Sham.
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All MI rats showed evidence of heart failure, including
development of LV dilatation and LV systolic dysfunc-
tion at both 3 weeks and 12 weeks after MI. Three
weeks after MI, there was a significant decrease in all
MI groups in FS and LVEF compared with the sham-
operated group, as well as an enlarged chamber size
(LVID) and a thinner wall thickness (IVS) in both sys-
tole and diastole (Table 2). During the following 9
weeks, a continued LV chamber enlargement and
interventricular septum wall thinning was observed in
all MI groups compared with the sham group.
Although most echocardiographic parameters were not
significantly different between the MI control group
and the vildagliptin-treated groups, comparisons
between 3 weeks and 12 weeks echocardiographic stu-
dies demonstrated that the progressive LV dilatation
and wall thinning in the MI control group was
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Figure 2 Effects of Vildagliptin on infarct size. A: Sirius red and fast green staining of rat myocardium shows the infarcted area with the red
color in all groups. B:Graphic representation of infarct size expressed as percentage of the scar length to the total LV circumference. Data are
presented as means ±SEM. N = 8-10 for all groups.
Table 2 Echocardiographic parameters of the experimental groups at week 3 and week 12.
Week 3 Week 12
Sham MI MI+VI MI+VL Sham MI MI+VI MI+VL
N=8 N=1 0 N=9 N=9 N=8 N=1 0 N=9 N=9
HR (bpm) 377 ± 11 379 ± 9 383 ± 11 407 ± 11 370 ± 12 387 ± 6 377 ± 10 391 ± 6
IVSd(mm) 1.5 ± 0.1 0.9 ± 0.1** 1.0 ± 0.01* 1.0 ± 0.1* 1.6 ± 0.1 0.8 ± 0.1** 1.0 ± 0.1* 0.8 ± 0.1**
LVIDd(mm) 7.7 ± 0.1 8.3 ± 0.3 8.4 ± 0.2 8.1 ± 0.3 8.0 ± 0.4 10.1 ± 0.3** § 9.7 ± 0.4** § 9.7 ± 0.2 ** §
LVPWd(mm) 1.8 ± 0.1 1.8 ± 0.1 1.9 ± 0.1 1.8 ± 0.1 2.1 ± 0.2 2.3 ± 0.2 2.0 ± 0.12 2.0 ± 0.1
IVSs(mm) 2.9 ± 0.1 1.3 ± 0.2* 2.0 ± 0.6 1.3 ± 0.2* 2.9 ± 0.2 1.0 ± 0.2** 1.2 ± 0.2** 1.2 ± 0.2**
LVIDs(mm) 4.2 ± 0.1 6.5 ± 0.3** 6.0 ± 0.4** 6.3 ± 0.3** 4.6 ± 0.4 8.6 ± 0.5** § 7.7 ± 0.4** 7.6 ± 0.2** §
LVPWs(mm) 2.9 ± 0.1 2.7 ± 0.1 2.6 ± 0.2 2.5 ± 0.1 2.9 ± 0.2 2.7 ± 0.3 2.6 ± 0.1 2.6 ± 0.2
LVEF (%) 82 ± 1 49 ± 3** 48 ± 4** 49 ± 3** 78 ± 3 36 ± 5** § 45 ± 5** 48 ± 4**
FS (%) 46 ± 2 22 ± 2** 21 ± 2** 22 ± 2** 43 ± 3 16 ± 3**§ 21 ± 2** 22 ± 2**
Data are presented as means ± SEM; N indicates number of animals; bpm, beats per minute. **P < 0.01 and *P < 0.05 indicate significant differences compared
to sham-operated rats in week 3 and week 12 respectively; § P < 0.05 indicates significant difference between parameters at week 12 and week 3 using Paired-
Sample T-Test. IVSd and IVSs, the thickness of the interventricular septum in diastole and systole; LVIDd and LVIDs, diastolic and systolic left ventricle dimensions;
LVPWd and LVPWs, the thickness of left ventricle posterior wall in diastole and systole.
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The LVEF in MI control group decreased from 49 ±
3% at 3 weeks to 36 ± 5% at 12 weeks, while in the
early vildagliptin it decreased from 48 ± 4% to 45 ±
5%, and in the late vildagliptin group from 49 ± 3% to
48 ± 4% (Table 2). The differences in LVEF at 12
weeks between the MI-control and the MI-vildagliptin
groups were not significant. Thus, a significant worsen-
ing of LVEF was observed in the MI control group as
compared to both vildagliptin groups.
Hemodynamic abnormalities were characteristic for
rats with HF in the MI control group. Specifically, MI
control rats showed significantly depressed dp/dtmax
and elevated LVEDP compared with sham operated rats,
while early and late vildagliptin treatment did not result
in significant improvement (Table 3).
Capillary density and cardiomyocyte size
Capillary density was significantly reduced in all post-MI
groups compared to sham-operated rats (p < 0.01) (Fig-
ure 3). Cardiomyocyte size significantly increased in all
post-MI groups compared to sham (p < 0.01). Vildaglip-
tin treatment both in early and late phase led to a trend
towards diminished cardiomyocyte hypertrophy but no
statistically significant effects were found compared to
the MI control group ((Figure 4, p = NS).
Cardiac gene expression
ANP and BNP mRNA levels were significantly increased
both in the MI control group as well in as late vildaglip-
tin treatment group compared to sham group (p < 0.05).
Vildagliptin treatment both in early and late phase had
no significant effects herein (Figure 5A and 5B). Similar
Table 3 Hemodynamic parameters of the experimental groups at sacrifice (12 weeks).
Sham
N=8
MI
N=1 0
MI-VI
N=9
MI-VL
N=9
Heart rate (bpm) 346 ± 16 378 ± 7 350 ± 9 361 ± 12
LVESP (mmHg) 117 ± 4 109 ± 3 108 ± 3 109 ± 4
LVEDP (mmHg) 6.2 ± 0.8 9.6 ± 1.6* 9.8 ± 1.3* 7.4 ± 0.5
SBP (mmHg) 115 ± 3 111 ± 2 110 ± 3 113 ± 3
DBP (mmHg) 87 ± 2 86 ± 2 85 ± 2 84 ± 2
dPdtmax (mmHg/s) 8744 ± 435 7245 ± 436 6908 ± 396 7952 ± 484
dPdtmin (mmHg/s) -9363 ± 268 -6419 ± 466* -6592 ± 613* -7077 ± 380*
Data are presented as means ± SEM; N indicates number of animals; LVESP, left ventricular end-systolic pressure; LVEDP, left ventricular end-diastolic pressure;
SBP, systolic blood pressure; DBP, diastolic blood pressure; dP/dtmax and dP/dtmin, the maximal rate of increase and decrease of left ventricular pressure,
respectively.*P < 0.05 vs. Sham.
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Figure 3 Effects of vildagliptin on capillary density in cardiomyocyte cross-sectional area. A: Graphic representation of capillary density
expresses as the number of capillaries/mm
2 field. B: Typical examples of capillary density in the experimental groups at ×40 magnification. Data
are presented as means ± SEM. N = 8-10 for all groups. **P < 0.01 vs. sham group.
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significantly increased in the MI group compared to
sham, while no difference was observed in collagen I
expression between vildagliptin-treated groups and the
control MI group (Figure 5C). MMP-9 mRNA levels
were similar in all groups (Figure 5D).
Discussion
In the present study, we demonstrate that long-term
treatment of the DPP-4 inhibitor vildagliptin in rats
with LV remodeling due to MI increases endogenous
active plasma GLP-1 levels, via inhibition of DPP-4
activity. However, this did not result in a decreased
infarct size nor did it attenuate cardiac remodeling asso-
ciated with post-MI. No differences in glucose levels
and body weight were found in these non-diabetic rats
when treated with vildagliptin.
To our knowledge, this is the first study to assess the
effects of immediate and late vildagliptin treatment in a
non-diabetic rat model. We furthermore aimed to dis-
sect immediate versus late effects of DPP-4 inhibition.
We herein show that neither early nor late vildagliptin
treatments exert beneficial effects in MI-induced dete-
rioration in cardiac remodeling. Notably, MI size was
(non-significantly) smaller in the vildagliptin treated
rats. However, this effect was observed both in rats
immediately treated with vildagliptin as well as in rats in
which treatment with vildagliptin started after 3 weeks,
so when the infarction scar is fully organized. From this,
we postulate that vildagliptin is unlikely to reduce
infarct size. The associated differences in LVEF may be
ascribed to the differences in infarct size. Other mea-
sures of LV remodeling were also unaffected by vilda-
gliptin. For example, both early and late vildagliptin
treatment did not reverse the MI-induced decrease in
capillary density, measured at the border zone of the
infarcted myocardium. Similarly, both early and late vil-
dagliptin treatment did not counteract MI-induced car-
diomyocyte hypertrophy. Furthermore, both early and
late vildagliptin treatment had no effects on the MI-
induced increases in cardiac expression of ANP, BNP.
ANP and BNP cardiac gene expression closely associates
with the severity of LV dysfunction [23], so this finding
supports the notion that cardiac remodeling is not
affected by vildagliptin. Furthermore, the expression of
matricellular proteins collagen I and MMP-9 were also
not affected by vildagliptin treatment.
A number of acute studies have been previously per-
formed with DPP-4 inhibitors, GLP-1 or GLP-1 analo-
gues, addressing their role in cardioprotection. A study
with the DPP-4 inhibitor PFK275-055, a vildagliptin-
analogue, showed a reduced infarct size with activation
of the cardioprotective RISK (reperfusion-induced sal-
vage kinase) pathway in pre-diabetic rats [24], whereas a
study with the DPP-4 inhibitor sitagliptin showed that
infarct size or short-term cardiac function were not
affected by the treatment [25]. The latter study is in line
with our study.
Another mean of increasing GLP-1 is direct GLP-1
infusion. Acute GLP-1 infusion studies both in patients
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Figure 4 Cardiomyocyte size was measured by gomori staining in cross-sectional areas. A: Graphic representation of cardiomyocyte size
in all experimental groups. B: Typical examples of cardiomyocyte size in the experimental groups at ×40 magnification. Data are presented as
means ± SEM. N = 8-10 for all groups. **P < 0.01 vs. sham group.
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study, 3-day infusion of GLP-1 improved LV function in
patients after acute MI [14]. Moreover, ischemia/reper-
fusion experiments in rats showed that GLP-1 adminis-
tration prior to the ischemia leads to smaller infarct size
in the isolated heart [11,12,26]. Another ischemia-reper-
fusion study showed that only the GLP-1 analogue exen-
din-4, but not GLP-1(9-36) amide exerts infarct-limiting
action, while both of them improved LV performance
[27]. Apparently, GLP-1 infusion provides a stronger
effect than DPP-4 inhibition, probably due to a stronger
elevation of GLP-1 levels. The published results from
DPP-4 inhibition studies are variable and this might be
explained by different levels of inhibition (different inhi-
bitors used, different dosages), and variable levels of
GLP-1.
So, although a number of acute studies have been per-
formed, only few chronic studies have addressed the
effects of GLP-1 on cardiac function in non-diabetic
models. A chronic (3 month) infusion study showed
that GLP-1 improved LV systolic function and pro-
longed survival in spontaneously hypertensive rats by
increasing myocardial glucose uptake and reducing myo-
cyte apoptosis [28]. Treatment with either GLP-1 or
exenatide analogue AC3174 also demonstrated promis-
ing cardioprotective effects, including improved LVEF,
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Figure 5 Quantitative real-time reverse-transcriptase polymerase chain reaction (RT-PCR) was conducted and expression was
measured of myocardial atrial natriuretic peptide (ANP; A), brain natriuretic peptide (BNP; B), collagen I (C), and matrix
metalloproteinase-9 (MMP-9; D), respectively (mRNA corrected for 36B4 mRNA level). The relative corrected values are shown for each
group. Data are presented as means ± SEM. N = 8-10 for all groups.*P < 0.05 vs. sham group.
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Page 8 of 10LV end-diastolic pressure, and cardiac dimensions in a
rat MI model (comparable to the present model) [29].
Our results are not in concert with the observations
that cardioprotection is achieved by GLP-1 treatment.
The reasons for the discrepancies between the present
study and earlier work may be attributable to the dosing
regimen, the different analogue utilized, the levels of
GLP-1 achieved, and the timing of the treatment and
the species studied [30].
Furthermore, a number of other issues should be con-
sidered when discussing the lack of vildagliptin-induced
cardioprotection as observed in our study. First, we used
a model of non-diabetic rats, with normal glucose levels.
Vildagliptin is an antidiabetic agent which exerts its
beneficial effects in the cardiovascular system through
glycometabolic control. Thus it may be possible that vil-
dagliptin is more beneficial in diabetic models. Second,
as a DPP-4 inhibitor, vildagliptin inhibits degradation of
GLP-1 and prolongs its half life in vivo;h o w e v e r ,i t s
effects are less strong than continuous GLP-1 infusion.
The elevations in GLP-1 levels achieved by vildagliptin
are likely to be lower than achieved by GLP-1 infusion
and thus insufficient to produce cardioprotection.
Finally, we do not know if other, hitherto unknown
mechanisms, may underpin the effects of vildagliptin in
the heart. To date, limited data are available describing
the effects of vildagliptin on the cardiovascular system.
In addition, the biological effects of DPP-4 inhibitors
appear different from GLP-1 and other GLP-1R agonists
[31]. Vildagliptin treatment has no effect on body
weight, food intake, energy expenditure and insulin sen-
sitivity [4,32,33]. Although it has been shown that vilda-
gliptin reduced plasma cholesterol and triglycerides in
diabetic patients [34,35], no effects of vildagliptin on
these parameters were found in our post-MI animal
study. However, GLP-1 inhibits glucagon secretion and
controls body weight by decreasing food intake, increase
insulin sensitivity and improve glucose uptake, which
are beneficial cardiovascular factors [36-38]. Moreover,
the protective effects of GLP-1 are also mediated
through GLP-1R-independent pathways, partially though
beneficial effects of its metabolite GLP-1 (9-36) [39].
These differences might explain why we observed only
limited improvements in our study with vildagliptin as
compared to other studies with GLP-1 and GLP-1
analogues.
Limitations
Possibly, the dosage of vildagliptin was not sufficient to
observe a cardioprotective effect of vildagliptin. We did
not include a group treated with GLP-1 infusion so we
cannot compare DPP-4 inhibition to GLP-1. Further-
more, although plasma glucose was comparable in all
groups, we did not assess factors associated with
myocardial glucose metabolism, so that we cannot rule
out if direct metabolic effects explain the results.
Conclusions
Long-term treatment with the DPP-4 inhibitor vildaglip-
tin, started immediate or late after MI, does not pre-
serve cardiac function in a rat post-MI remodeling
model of chronic heart failure despite increases in
plasma active GLP-1 levels by inhibiting DPP-4 activity.
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